Agios Pharmaceuticals (AGIO) Share-based Compensation (2012 - 2026)

Agios Pharmaceuticals' Share-based Compensation history runs 15 years deep, the most recent figure standing at $15.5 million for Q1 2026.

• Quarterly Share-based Compensation rose 36.82% year-over-year to $15.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.7 million (up 26.15% YoY) and the FY2025 annual result came in at $52.6 million, up 22.65% from the prior year.
• Share-based Compensation was $15.5 million for Q1 2026 at Agios Pharmaceuticals, up from $14.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $15.5 million in Q1 2026 and bottomed at $9.1 million in Q3 2023.
• A 5-year average of $12.1 million and a median of $11.5 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation plunged 34.63% — and 2026, when it soared 36.82%.
• Agios Pharmaceuticals' Share-based Compensation stood at $11.5 million in 2022, then advanced by 20.49% to $13.8 million in 2023, then dropped by 21.07% to $10.9 million in 2024, then increased by 29.54% to $14.1 million in 2025, then advanced by 10.03% to $15.5 million in 2026.
• Business Quant data shows AGIO's Share-based Compensation at $15.5 million in Q1 2026, $14.1 million in Q4 2025, and $12.4 million in Q3 2025.